NCT04494321View on ClinicalTrials.gov

A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block

PHASE1CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

June 19, 2017

Primary Completion Date

November 17, 2017

Study Completion Date

November 17, 2017

Conditions
AsthmaCOPD
Interventions
DRUG

Budesonide

Inhaled corticosteroid

DRUG

Formoterol

Long Acting Beta Agonist (LABA)

Trial Locations (1)

Unknown

Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch, New Taipei City

Sponsors
All Listed Sponsors
lead

Intech Biopharm Ltd.

INDUSTRY

NCT04494321 - A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block | Biotech Hunter | Biotech Hunter